Stockreport

BRIEF-Genentech Says FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies [Reuters]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF BRIEF-Genentech Says FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies | Reuters Reuters Staff 1 Min Read Aug 13 (Reuters) - Genente [Read more]